Drug Approval | August 20, 2022
Swissmedic approves Kapruvia with additional regulatory decisions expected in H2 2022
Therapy recently approved in Canada under the brand name KORSUVA
Therapy recently approved in Canada under the brand name KORSUVA
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Merck is organizing one of the biggest South APAC Virtual Conclave on ‘Next-Gen Labs’ on 20th July.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Subscribe To Our Newsletter & Stay Updated
